Provided by Tiger Trade Technology Pte. Ltd.

InMed Pharmaceuticals Inc

1.36
-0.0300-2.16%
Post-market: 1.360.00000.00%16:10 EDT
Volume:10.31K
Turnover:14.18K
Market Cap:7.47M
PE:-0.58
High:1.40
Open:1.39
Low:1.36
Close:1.39
52wk High:2.50
52wk Low:0.5750
Shares:5.49M
Float Shares:2.15M
Volume Ratio:0.10
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3525
EPS(LYR):-8.3630
ROE:-156.77%
ROA:-66.46%
PB:6.95
PE(LYR):-0.16

Loading ...

InMed Pharmaceuticals agrees to all-stock merger with Mentari Therapeutics

Reuters
·
May 19

InMed Pharmaceuticals: InMed Shareholders Are Expected to Own Approximately 1.51% of Combined Company

THOMSON REUTERS
·
May 19

InMed Pharmaceuticals: Post Deal, Combined Company to Have Pro Forma Equity Value of About US$421.4 Mln (Inclusive of Private Placement)

THOMSON REUTERS
·
May 19

Press Release: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Dow Jones
·
May 19

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM

Reuters
·
May 19

InMed net loss widens 40% to USD 2.97 million in Q3 FY26

Reuters
·
May 07

FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification

Reuters
·
Apr 30

InMed Pharmaceuticals files prospectus supplement for at-the-market common share offering

Reuters
·
Apr 04

InMed receives Nasdaq notification regarding minimum bid price compliance

TIPRANKS
·
Mar 30

InMed Pharmaceuticals drops on Nasdaq notice; bid price stays below $1.00 for 30 straight sessions

Reuters
·
Mar 28

InMed Pharmaceuticals announces preclinical data on effects of INM-901

TIPRANKS
·
Mar 23

InMed Pharmaceuticals Inc - Announces Positive Data Supporting Inm-901 Alzheimer's Program - SEC Filing

THOMSON REUTERS
·
Mar 23

InMed Pharmaceuticals Inc - Targets Ind Submission and Phase 1 Clinical Trial for Inm-901 in 2027 - SEC Filing

THOMSON REUTERS
·
Mar 23

InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models

Reuters
·
Mar 23